Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Marina Petrova advises European and U.S. clients on a broad range of complex cross-border transactions, including venture capital financings ranging from seed funding to crossover rounds, M&A transactions, and international securities offerings.

  • Advised U.S. digital health startup in connection with a convertible seed preferred stock investment, followed by an issuance of convertible notes and a $7.5 million Series A fundraise.
  • Advised UK biotech in connection with its £25 million Series A and its £65 million Series B fundraise.
  • Advised the venture arm of a NYSE-listed U.S. software company in relation to the Series B and Series C2 fundraises of a UK SaaS startup.
  • Advised European impact investor in the Series C fundraise of a Mexican producer of biodigesters for small and medium-sized farms.
  • Advised Mission Therapeutics Limited, a UK drug discovery and development company, on its Series C equity fundraise of up to £60 million.
  • Advised European biotech on its acquisition of assets and infrastructure from a Nasdaq-listed U.S. biotech in a Chapter 11 bankruptcy process.
  • Advised Vernalis plc, a UK pharmaceutical company, in its acquisition of the U.S. rights to amoxicillin extended-release tablets from Pragma Pharmaceuticals.
  • Advised a UK online retailer of health, beauty, fitness and lifestyle products in its acquisitions of three U.S. specialist online retailers.
  • Advised Oxford BioMedica plc, an LSE-listed biopharmaceutical company, in relation to a $50-million secured term loan facility.
  • Advised LSE-listed UK pharmaceutical company in relation to a potential placing and open offer with a Rule144A component.
  • Advised the joint book runners in relation to the £121 million LSE initial public offering and Rule 144A placing of a specialist retailer of video games.
  • Advised the joint book runners in relation to an LSE-listed European transportation company’s potential follow-on issue of shares and Rule 144A placing.
  • Advised a Chinese service provider in the oil and gas industry, on its international placing of shares to cornerstone investors under Regulation S in conjunction with a Hong Kong IPO.
  • Advised target in relation to the global merger control review of its acquisition by a multinational life sciences company for $13.6 billion.

Previous Experience

  • Corporate associate at an international law firm.
  • Legal intern at the Berkman Center for Internet and Society, Harvard Law School.